

The TradeXchange notable news from last week (1/3-1/6) that stood out for a possible upcoming trade opportunity. Also notes from the [previous week's](#) notable news. TradeXchange news are in bold followed by a brief analysis.

1/6

LOXO FORM SC 13G Filed by Adage Capital Partners, LP 5.28%

LOXO ini with a buy at BTIG. \$52 PT

Adage increased stake from 817,500 shares to 1350,000. A lot of reputable funds own this stock. It's only in phase II trials, but could go much higher from here. It's flagship drug showed promise in recent trial results. It's already 10% above its 1/5 offering price of \$31 per share. That's one indication that the stock will keep going higher, into the \$40s.

LOXO seeks to treat very rare forms of cancer, and none of its pipeline is in ph 3 trials yet. One might think the stock is overvalued at \$800M market cap. The fact that so many astute funds own the stock and are increasing their position should give short sellers caution.

1/5

KBIO – KaloBios announces positive guidance from FDA for Benznidazole

Keep on watch. If the FDA gives a clear path for approval, then KBIO could go on another run.

MEET – MeetMe Reports preliminary 4th quarter revenue results above its previously released guidance

Online dating and online social chatting has increased in popularity recently and is a hot sector. MEET likely will run up higher into its Q416 earnings report in early March. Trading in the low \$5s, it's still far below its 52 week high of \$8.

1/3 WATT – JT Group invests in Energous and becomes preferred technology solutions partner for IoT connectivity

More and more informed investors are investing in WATT. This could mean the technology is legit. Be on watch for more newsflow and another breakout in WATT.

PCRX initiated with a Buy at HC Wainwright, \$43 PT

PCRX has a post surgery pain relief drug that's safer than opioids. It sold better than expected from the Q416 earnings report. Stock likely will keep going up.

From the [previous week's trade ideas](#) (12/27-12/30)

CEMP bounced as most smallcap biotech stocks do after they get crushed. Closed on 1/6 at \$3.75.

NVDA faded slightly further from last week and closed at \$103.1 on 1/6.